This trial uses two existing cancer drugs to see if jointly they increase the survival rate.
Given the ugly side effects, and the liklihood that a marginal but improved outcome is found - I would call this a complimentary treatment to cvac, and possibly subordinate.
The main competition I see (and again it will probably be complimentary) is NV-128 by Novogen but hasn't begun human trials yet.
One of the main pluses to cvac is doesn't have the nasty side effects of chemo and the drugs in the trial above.
This trial uses two existing cancer drugs to see if jointly they...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.005(2.08%) |
Mkt cap ! $357.7M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 24.5¢ | 24.0¢ | $48.75K | 199.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 492298 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 634832 | 27 |
View Market Depth
| Last trade - 14.06pm 02/07/2025 (20 minute delay) ? |
| IMM (ASX) Chart |